Literature DB >> 17940341

Second primary tumors following a diagnosis of meningioma in Sweden, 1958-1997.

Faith Davis1, Björn Tavelin, James Grutsch, Beatrice Malmer.   

Abstract

This study quantifies the risk of second primary tumors following a diagnosis of meningioma. 12,012 meningiomas and 926 second primary cancers were identified (ICD7, path code 461) between 1958 and 1997 using Swedish Cancer Registry data. Standardized incidence ratios (SIRs) and exact 95% confidence intervals (CIs) were calculated. An elevated risk of any second primary cancer diagnosis (SIR = 1.2, 95% CI = 1.1-1.3) was observed. Elevated and statistically significant SIRs were observed for renal cancer (SIR = 1.6), melanoma (SIR = 1.7), thyroid cancer (SIR = 2.6) and brain tumors (SIR = 2.6). A consistent pattern of risk over time supports the evaluation of common risk factor profiles for renal, melanoma and thyroid cancers. Radiation exposures increase the risk of these rare tumors, so quantifying the cumulative and shared effects of environmental and treatment exposures is of further interest. (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2007        PMID: 17940341     DOI: 10.1159/000109823

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  3 in total

1.  Treatment-related secondary cancer in malignant meningiomas: a population-based study.

Authors:  Xuhui Bao; Lanfang Cao; Hailan Piao; Liyi Xie
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-08       Impact factor: 4.553

2.  Medical diagnostic radiation exposures and risk of gliomas.

Authors:  Faith Davis; Dora Il'yasova; Kristin Rankin; Bridget McCarthy; Darell D Bigner
Journal:  Radiat Res       Date:  2011-04-05       Impact factor: 2.841

3.  Secondary cancer after meningioma diagnosis: an Israeli national study.

Authors:  Maya Ben Lassan; Yael Laitman; Lital Keinan-Boker; Barbara Silverman; Eitan Friedman
Journal:  Cancer Causes Control       Date:  2022-07-24       Impact factor: 2.532

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.